Diagnostic Considerations in H1N1 Influenza-induced Thrombotic Microangiopathy
- PMID: 33369997
- DOI: 10.1097/MPH.0000000000002036
Diagnostic Considerations in H1N1 Influenza-induced Thrombotic Microangiopathy
Abstract
Influenza virus can trigger atypical hemolytic uremic syndrome and present with complement-driven thrombotic microangiopathy (TMA). When administered promptly, complement-blocking therapies can spare organ injury and be lifesaving. However, diagnosing TMA in the setting of a severe viral infection can be challenging, as a significant overlap of symptoms and disease complications exists. This is particularly true in influenza virus infections and more recently, Coronavirus disease 2019 (COVID-19) infections. We present a 16-year-old male with H1N1 influenza-induced atypical hemolytic uremic syndrome who quickly improved with complement-blocking therapy, highlighting an urgent need to include TMA in the differential diagnosis of severe viral infections.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:654–666.
-
- Lapeyraque AL, Bitzan M, Al-Dakkak I, et al. Clinical characteristics and outcome of Canadian patients diagnosed with atypical hemolytic uremic syndrome. Can J Kidney Health Dis. 2020;7:1–9.
-
- Hofer J, Rosales A, Fischer C, et al. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Front Pediatr. 2014;2:97.
-
- Shieh WJ, Blau DM, Denison AM, et al. 2009 Pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol. 2010;177:166–175.
-
- Fox SE, Akmatbekov A, Harbert JL, et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8:681–686.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical